Bioventus Inc. (BVS) Earnings Call Transcripts

Bioventus Inc.'s Latest Earnings Call - June 8, 2026

Bioventus Inc. reported a promising outlook for fiscal year 2026, with guidance set at $605 million, up from $568 million in 2025. The company achieved a 7% revenue growth in Q1 2026, with significant improvements in EBITDA and EPS, which grew by 25% and 100% respectively. Management maintained revenue guidance but raised EPS and free cash flow guidance, reflecting strong profitability and cash flow management. Key growth drivers include the Peripheral Nerve Stimulation (PNS) and Platelet-Rich Plasma (PRP) products, which are expected to contribute 200 basis points to growth for the year.

Reported metrics

Guidance from management

Bioventus maintained its revenue guidance for 2026 at $605 million but raised EPS and free cash flow guidance, reflecting strong profitability and cash flow management.

What management said

The other thing I'd hit on is cash flow. So significant $28 million increase in cash flow in Q1. As Mark talked about, that's been a big turnaround part of the story. We continue to see that momentum build as we've gone throughout the year.

Yes, I think we really just focused on the impact that, that has on our business, and it really affects 50% of our business, this new news on the reimbursement. So when you look at the amount that was impacted from a full year perspective, it was really immaterial. When you also look at our competitors who are also impacted, they had some significant reductions in their revenue and profit that they adjusted with the ...

What analysts pressed on

Analysts expressed concerns about the impact of CMS reimbursement changes on the Exogene business and sought clarity on how Bioventus plans to mitigate these effects. There were also questions about the sustainability of growth in the face of competitive pressures and the balance between investment and margin expansion.

Main topics on the call

• Revenue Growth — Bioventus reported a 7% revenue growth in Q1 2026, driven by strong performance across its segments. Management expects this growth to accelerate as the year progresses, particularly in the Surgical business.
• Profitability Improvements — The company achieved a 25% increase in EBITDA and a 100% increase in EPS year-over-year in Q1 2026, attributed to effective P&L management and reduced interest expenses from debt reduction.
• Guidance and Market Conditions — Despite changes in CMS reimbursement affecting 50% of the Exogene business, Bioventus maintained its revenue guidance, citing immaterial impacts and competitive advantages.
• Product Portfolio and Growth Drivers — Bioventus is focusing on its PNS and PRP products, which are expected to contribute significantly to growth. The PNS market is a $250 million opportunity growing at 25% annually.

Read the full Bioventus Inc. transcript (June 8, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 48 Bioventus Inc. earnings call transcripts on record, spanning February 19, 2020 to June 8, 2026. Based on this history, Bioventus Inc. reports quarterly. The most recent call on file is dated June 8, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

BVS

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

48

First call

February 19, 2020

Most recent

June 8, 2026

Reporting cadence

quarterly